The MagCapturer circulating tumor cell separator is a benchtop instrument from Advanced Gene Diagnostics designed to enrich circulating tumor cells from peripheral blood. As tumors evolve under therapy, the composition of these rare cells can shift in ways that foreshadow treatment resistance. Capturing them from a routine blood draw offers a minimally invasive window into tumor dynamics. This article examines how CTC enrichment supports resistance monitoring and sequencing decisions in a research or companion-diagnostics workflow.
The instrument uses immunomagnetic capture: beads conjugated to anti-EpCAM bind epithelial markers on tumor cells, allowing them to be separated from abundant leukocytes on a magnetic column. Both positive enrichment, which captures EpCAM-positive cells, and negative depletion strategies can be applied, improving recovery across tumor types with variable epithelial marker expression. A processing volume of roughly one to ten milliliters of whole blood is sufficient, which keeps the procedure convenient for serial sampling.
In this context indications means validated research applications. The MagCapturer is used for CTC enrichment in oncology research, liquid biopsy development, and exploration of minimal residual disease. It is positioned for laboratories studying how circulating tumor cells relate to disease progression rather than for stand-alone clinical diagnosis.
Acquired resistance remains a central challenge in cancer care, and tissue re-biopsy is not always feasible. Circulating tumor cells provide a blood-based surrogate that can be analyzed for phenotype and molecular changes associated with escape from therapy. By sampling before and during treatment, researchers can observe shifts in cell burden and marker expression that may signal emerging resistance. This information supports the design of sequential or combination regimens and helps prioritize which resistance mechanisms to probe further. Such workflows are research-grade and should be interpreted alongside standard clinical assessments rather than replacing them.
Q: What sample volume does the MagCapturer require? A: The system processes approximately one to ten milliliters of whole blood, allowing repeated draws without imposing a heavy burden on the patient or donor.
Q: How does EpCAM-based capture relate to resistance studies? A: EpCAM capture isolates epithelial tumor cells from blood; tracking these cells over time reveals changes in burden and phenotype that can precede clinically evident resistance.
Q: Can the instrument perform negative enrichment as well? A: Yes. Beyond positive EpCAM capture, the platform supports depletion-based strategies, which helps recover tumor cells that have downregulated epithelial markers during disease progression.
The MagCapturer circulating tumor cell separator is a benchtop instrument from Advanced Gene Diagnostics designed to enrich circulating tumor cells from peripheral blood. As tumors evolve under therapy, the composition of these rare cells can shift in ways that foreshadow treatment resistance. Capturing them from a routine blood draw offers a minimally invasive window into tumor dynamics. This article examines how CTC enrichment supports resistance monitoring and sequencing decisions in a research or companion-diagnostics workflow.
The instrument uses immunomagnetic capture: beads conjugated to anti-EpCAM bind epithelial markers on tumor cells, allowing them to be separated from abundant leukocytes on a magnetic column. Both positive enrichment, which captures EpCAM-positive cells, and negative depletion strategies can be applied, improving recovery across tumor types with variable epithelial marker expression. A processing volume of roughly one to ten milliliters of whole blood is sufficient, which keeps the procedure convenient for serial sampling.
In this context indications means validated research applications. The MagCapturer is used for CTC enrichment in oncology research, liquid biopsy development, and exploration of minimal residual disease. It is positioned for laboratories studying how circulating tumor cells relate to disease progression rather than for stand-alone clinical diagnosis.
Acquired resistance remains a central challenge in cancer care, and tissue re-biopsy is not always feasible. Circulating tumor cells provide a blood-based surrogate that can be analyzed for phenotype and molecular changes associated with escape from therapy. By sampling before and during treatment, researchers can observe shifts in cell burden and marker expression that may signal emerging resistance. This information supports the design of sequential or combination regimens and helps prioritize which resistance mechanisms to probe further. Such workflows are research-grade and should be interpreted alongside standard clinical assessments rather than replacing them.
Q: What sample volume does the MagCapturer require? A: The system processes approximately one to ten milliliters of whole blood, allowing repeated draws without imposing a heavy burden on the patient or donor.
Q: How does EpCAM-based capture relate to resistance studies? A: EpCAM capture isolates epithelial tumor cells from blood; tracking these cells over time reveals changes in burden and phenotype that can precede clinically evident resistance.
Q: Can the instrument perform negative enrichment as well? A: Yes. Beyond positive EpCAM capture, the platform supports depletion-based strategies, which helps recover tumor cells that have downregulated epithelial markers during disease progression.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
